Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Neurotoxic anticancer drugs, such as platinum-based anticancer drugs, taxanes, vinca
alkaloids, and proteasome/angiogenesis inhibitors are responsible for chemotherapy …

ATP-binding cassette transporter B1 (ABCB1; P-glycoprotein; multidrug resistance protein 1)
is an adenosine triphosphate (ATP)-dependent efflux transporter located in the plasma …

Commonly used chemotherapeutic agents in oncology/hematology practice, causing toxic
peripheral neuropathy, include taxanes, platinum compounds, vinca alkaloids, proteasome …

Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

The MDR1 (ABCB1) gene encodes a membrane-bound transporter that actively effluxes a
wide range of compounds from cells. The overexpression of MDR1 by multidrug-resistant …

Prostate cancer is one of the most frequently diagnosed malignancies in developed
countries and approximately 248,530 new cases of prostate cancer are likely to be …

Docetaxel (Taxotere®) has been one of the most important chemotherapeutic drugs for
cancer treatment since 1996. Although a large number of clinical studies have been …

Patients with metastatic castration-resistant prostate cancer (mCPRC) now have an
unprecedented number of approved treatment options, including chemotherapies …

The treatment of metastatic castrate-resistant prostate cancer has been historically
challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy …